Trial Condition(s):

Wet Macular Degeneration

Real Life of Aflibercept In FraNce: oBservatiOnnal study in Wet AMD (RAINBOW)

Bayer Identifier:

17374

ClinicalTrials.gov Identifier:

NCT02279537

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The purpose of this study is to collect real-life data on patients with wet age related macular degeneration (AMD) for whom treatment with Eylea was initiated

Inclusion Criteria
- Patient with a diagnosis of wet AMD will be enrolled after the decision for treatment with Aflibercept (Eylea) has been made
 - Patient with 1st injection of Eylea from 01 January 2014 until 30 April 2015 will be enrolled
 - Prior/current treatment with any anti-VEGF intravitreal injections or macular laser (laser and/or visudyne/PDT) in the fellow eye is allowed
 - Man or woman aged 18 years or more
 - Patient who has been given appropriate information about the study objectives and procedures and who has given his/her written, informed consent;
Exclusion Criteria
- Patient with another retinal disease: diabetic retinopathy, diabetic macular oedema (DME), myopic choroidal neovascularization, retinal vein occlusion (RVO), central serous chorioretinopathy (CSC), angioid streaks
 - Patient who does not meet the local indication criteria for Eylea treatment.Contraindications listed in the Summary of  Product Characteristics (SmPC) must be taken into account
 - Patient who has previously been treated with any macular laser (laser and/or visudyne/PDT) or  any anti-VEGF intravitreal injections for the study eye
 - Patient taking part in an interventional study at the time of enrolment.

Trial Summary

Enrollment Goal
593
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, France

Status
Completed
 

Trial Design